For the primary evaluable population ( n = 63 for adjunctive edivoxetine and n = 68 for adjunctive placebo ) , the treatment groups did not differ significantly on the primary outcome of change from baseline to week 8 in the MADRS total score ; the effect size of edivoxetine treatment was 0.26 .